ArticleAnnals of clinical and translational neurology2023
The systemic inflammation markers as possible indices for predicting respiratory failure and outcome in patients with myasthenia gravis.
Article in Annals of clinical and translational neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 27 citations in OpenAlex.
- An Immune Model Incorporating NK Cells and IL-12 to Predict the Efficacy of the Initial Treatment Cycle of Efgartigimod in Generalized Myasthenia Gravis.Drug design, development and therapy · 2026Observational
- Real-world efficacy of eculizumab in generalized myasthenia gravis patients with poor early response to efgartigimod: a prospective cohort study.Frontiers in immunology · 2026Article
- Immune dysregulation driven by elevated platelet-to-lymphocyte ratio aggravates myasthenia gravis.The Journal of international medical research · 2026Article
- The Potential Implications of Neutrophil to Albumin Ratio for Short-term Prognosis in Myasthenia Gravis Patients.Molecular neurobiology · 2025Article
- Platelet activation plays a pro-inflammatory role in myasthenia gravis.Nature communications · 2025Article
- The systemic inflammation markers as potential predictors of disease progression and survival time in amyotrophic lateral sclerosis.Frontiers in neuroscience · 2025Article
- Serum cystatin C as a potential biomarker for generalized acetylcholine receptor antibody-positive myasthenia gravis.Frontiers in immunology · 2025Article
- Association of systemic inflammatory factors with clinical outcomes in patients with autoimmune encephalitis at different clinical stages.Frontiers in immunology · 2025Article
- The Value of Combined Detection of Systemic Inflammation Response Index and Prognostic Nutritional Index in Predicting Short-Term Prognosis of Myasthenia Gravis.Journal of inflammation research · 2025Article
- Autoimmune and Non-Autoimmune Comorbidities in Myasthenic Patients of East-European Descent: A Case-Control Study.Journal of clinical medicine · 2024Article
- Systemic Inflammatory Response Index, a Potential Inflammatory Biomarker in Disease Severity of Myasthenia Gravis: A Pilot Retrospective Study.Journal of inflammation research · 2024Article
- Predictive value of the dynamic systemic immune-inflammation index in the prognosis of patients with intracerebral hemorrhage: a 10-year retrospective analysis.Frontiers in neurology · 2024Article
- Construction and Comparison of Multiple Serum-Based Prognostic Models for Predicting the Prognosis of Acute Exacerbations of Chronic Obstructive Pulmonary Disease.Journal of inflammation research · 2024Article
- Correlation between Cardiovascular Autonomic and Pulmonary Ventilation Functions in Myasthenia Gravis Patients.Advances in respiratory medicine · 2023Article
- Alterations in short-term blood pressure variability related to disease severity and autonomic symptoms in myasthenia gravis patients.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2023Article
- Comparison of immune cell profiles associated with heatstroke, sepsis, or cardiopulmonary bypass: Study protocol for an exploratory, case-control study trial.Frontiers in medicine · 2023Article
- Disease-specific divergence of inflammatory and metabolic biomarkers in neurocritical neuromuscular disorders.Frontiers in neurologyArticle
- Inflammatory biomarker panels in peripheral blood: association with myasthenia gravis onset and severity.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to explore the relationship between systemic inflammation markers and clinical activity, respiratory failure, and prognosis in patients with myasthenia gravis (MG).
methodsOne hundred and seventeen MG patients and 120 controls were enrolled in this study. Differences in the four immune-related markers of two groups based on blood cell counts: neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), lymphocyte to monocyte ratio (LMR), and systemic immune-inflammation index (SII) were measured. The stability of the associations between systemic inflammation markers and respiratory failure in MG patients was confirmed by adjusted logistic regression analysis. Moreover, Kaplan-Meier curve and multivariate COX regression models were applied to assess the factors affecting the outcome of MG.
resultsNLR, PLR, and SII were higher in MG patients than those in controls and were positively associated with MGFA classification, but not LMR. Adjusted logistic regression analysis showed that PLR was an independent predictor of MG with respiratory failure. The ROC curve demonstrated that PLR showed good sensitivity and specificity for the diagnosis of MG with respiratory failure. Kaplan-Meier curve showed that GMG, positive AchR-Ab, respiratory failure, high NLR, PLR, SII, and IVIg exposure correlated with the risk for poor outcomes in MG patients. The multivariate COX regression models indicated that GMG and high SII was a risk factor for poor outcome of MG.
interpretationThe systemic inflammation markers expressed abnormally in MG patients, in which PLR may be an independent predictor of respiratory failure, and high SII and GMG were predictive risk factors for poor outcomes in MG patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.